Lenacapavir Demonstrates 100% Effectiveness in HIV Prevention for At-Risk Young Women
8 Jul 2024 • Biannual injections of lenacapavir provided full protection against HIV in high-risk young women receiving pre-exposure prophylaxis (PrEP).
-
A clinical trial called Purpose in South Africa and Uganda tested lenacapavir's efficacy as pre-exposure prophylaxis (PrEP) for high-risk young women.
-
Administered twice yearly via subcutaneous injection, lenacapavir provided complete protection from HIV: none of the 2,134 women who received it contracted the virus. In contrast, among those taking oral PrEP pills, 16 out of 1,068 women became HIV-positive. This breakthrough offers a promising new HIV prevention strategy.
Source:Times Now| Read full story